Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.
Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.
Filgotinib’s mixed efficacy in ulcerative colitis prompts a shares slide.
Five years after failing phase II in Nash, elafibranor fails phase III in Nash; a focus on liver cirrhosis beckons.
Pivotal ulcerative colitis data on etrolizumab, a dual-action anti-integrin antibody, are due soon, and Roche has Takeda’s Entyvio in its sights.
Gilead and Galapagos's filgotinib might not be a match for Rinvoq in ulcerative colitis, while Menlo needs to prove serlopitant works after previous setbacks.